Assistance Publique Hopitaux De Paris — Sponsor Intelligence | 264 EU Trials

Filter these 264 trials by condition, phase, country and more.

Open in Search →

264 Registered trials

134 Recruiting

61 Completed trials

13 Countries active

346 Unique IMPs

100% Results reported

Phase III

Phase II

Phase III: 137 Phase II/III: 14 Phase II: 72 Phase I/II: 11 Phase III/IV: 6 Phase IV: 12 Phase I: 5 Phase I (Other): 2 Phase I (FiH): 5

Oversight events:

1 serious breach 12 temporary halts 9 urgent safety measures 2 unexpected events 8 corrective measures across 24 trials

View oversight register →

100%

61 of 61 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Sickle cell disease 3 Cutaneous T-cell lymphoma 2 Acute kidney injury 2 Giant cell arteritis 2 Granulomatosis with polyangiitis 2 Autism spectrum disorder 2 Ischaemic stroke 2 Atrial fibrillation 1 Neuromyopathy 1 B-cell lymphoma 1 Primary biliary cholangitis 1 Cardiac arrest 1

Top IMPs

ALLOGENEIC FAECAL MICROBIOTA, POOLED 10 SODIUM CHLORIDE 7 PLACEBO 6 PREDNISONE 5 ANAKINRA 4 CLOSTRIDIUM BOTULINUM NEUROTOXIN TYPE A (150KD), FREE OF COMPLEXING PROTEINS 4 RITUXIMAB 4 TOCILIZUMAB 4 ALDESLEUKIN 3 BARICITINIB 3 COLCHICINE 3 METHOXYFLURANE 99.9% 3

All trials — page 3

264 total

A Phase 2, single arm Multicenter, Study testing Mezigdomide, Carfilzomib, and Dexamethasone (480Kd) in Participants with Relapsed or Refrac… Pending

2025-521090-14-00 Phase II 1 country MEZIGDOMIDE
BeCALM - Brentuximab vedotin in CutAneous T-cell Lymphomas (CTCL): post-allogeneic hematopoietic stem cell transplant Maintenance Pending

2025-521093-34-00 Phase III 1 country BRENTUXIMAB VEDOTIN
CBD-SIB - Efficacy of cannabidiol in the management of Self-Injurious Behavior in children and adolescents with severe neurodevelopmental di… Pending

2025-521161-27-00 Phase II 1 country CANNABIDIOL
MAINRITSys : Rituximab vs placebo for maintenance in systemic sclerosis – interstitial lung disease Pending

2025-521331-36-00 Phase II/III 1 country RITUXIMAB
PALETTE - Trial for personalisation of sepsis treatment in children and adults Pending

2025-521371-31-00 Phase II 1 country HUMAN PLASMA PROTEIN
ANAKINRA IN THE TREATMENT OF PEDIATRIC ACUTE MYOCARDITIS Pending

2025-521478-32-00 Phase III 1 country ANAKINRA
PREV-CART - “A multicentric phase III randomized clinical trial open-label, comparing immunoglobulin replacement therapy (IgRT) and antibiot… Pending

2025-521571-30-00 Phase III 1 country
Impact of the timing of immunotherapy administration in metastatic lung cancers Pending

2025-521891-78-00 Phase III 1 country PEMBROLIZUMAB
Electrophysiological analysis of Gamma-Hydroxybutyrate-induced sleep in intensive care patients: A Pilot Double-Blind Randomized Controlled … Pending

2025-521967-11-00 Phase II 1 country SODIUM OXYBATE
ANTIMIDIS - Cefazolin mediastinal distribution using microdialysis Pending

2025-521988-13-00 Phase IV 1 country
PREP-ANCA - Comparison of a strategy based on clinic-biological surveillance versus pre-emptive treatment with rituximab in the event of ANC… Pending

2025-522049-23-00 Phase IV 1 country RITUXIMAB
Sustained-release oral morphine to alleviate persistent dyspnea in patients with chronic respiratory insufficiency due to amyotrophic latera… Pending

2025-522546-52-00 Phase III 1 country
Use of low doses of interleukin-2 in autism spectrum disorders Pending

2025-522841-23-00 Phase II 1 country ALDESLEUKIN
Effects of butyrate enemas on postoperative intestinal motility disorders in Hirschsprung’s disease Pending

2025-523094-42-00 Phase III 1 country SODIUM BUTYRATE
KARMA - INtenSive care TreAtmeNT with adjuvant KetAmine and Recovery after Mechanical ventilAtion: a multicenter doubleblind randomized cont… Pending

2025-523149-80-00 Phase II/III 1 country KETAMINE HYDROCHLORIDE
THERIPEX Pending

2025-523305-15-00 Phase I 1 country ALDESLEUKIN; FOXP3-T4
MAMI Use of the Methoxyflurane as pain-killer in the prehospital management of Acute Myocardial Infarction Pending

2025-523349-86-00 Phase III 1 country METHOXYFLURANE 99.9%
Efficacy of Temocillin compared to standard of care in the Treatment of Neisseria gonorrhoeae Infections: A Multicenter Randomized Controlle… Pending

2025-524475-23-00 Phase III 1 country TEMOCILLIN SODIUM
ACTIVATE - Phase 1 Clinical Trial evaluating the combination of Actinomycin D and venetoclax in patients with Relapsed/Refractory (R/R) Acut… Pending

2025-524728-22-01 Phase I/II 1 country
Dose dense re-challenge of high dose methotrexate (hd-mtx) with glucarpidase (cpg2) for relapsed primary cns lymphoma (pcnsl): A phase 1 tri… Recruiting

2024-511900-17-00 Phase I (Other) 1 country
Fecal transplantation to Eradicate Colonizing Emergent Superbugs Recruiting

2024-516393-29-00 Phase III 1 country ALLOGENEIC FAECAL MICROBIOTA, POOLED; PLACEBO
Lessening Organ Dysfunction with VITamin C in septic ARDS Recruiting

2024-516394-78-00 Phase III 1 country SODIUM ASCORBATE
Long–term Analysis of DImethyl fumarate, to slow the Growth of Areas of Geographic Atrophy Recruiting

2024-510741-33-00 Phase II 1 country
Rituximab in patients with ST-elevation myocardial infarction. A phase 2 placebo-controlled randomized clinical trial. Recruiting

2022-501893-21-00 Phase II 5 countries RITUXIMAB

Showing 49–72 of 264 trials

← All sponsors A–Z